Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#288 of 589

Andres Y. Maldonado

HC Wainwright & Co. · Equity Research Analyst
EstablishedRating since 2022No new ratings since Oct 2025

Analyst rating accuracy & track record

Andres Y. Maldonado is an equity research analyst at HC Wainwright & Co.. Quantellect has scored 41 of their stock calls across 14 companies. Their picks beat their sector 39% of the time over the next 12 months, and their price targets were reached 27% of the time within a year.

Win % vs sector
39%
PT Hit % (12mo)
27%
Avg sector-excess
−4.6%
Scored calls
41
Tickers
14
Tier
Established

Track record

Quantellect has scored 41 of Andres Y. Maldonado's stock calls across 14 companies, dating back to 2022. Their rated stocks beat their own sector 39% of the time over the next 12 months. On a typical call, a Maldonado pick returned −4.6% more than its sector over the following year.

Of the scored calls, 41 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
SNDXSyndax Pharmaceuticals Inc
Buy$40.00Oct 2025−22.9%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$40.00Oct 2025−102.1%Miss
SNDXSyndax Pharmaceuticals Inc
Buy$40.00Oct 2025−34.2%Miss
MNPRMonopar Therapeutics Inc
Buy$105.00Sep 2025−25.8%Hit
CADLCandel Therapeutics Inc
Buy$23.00Sep 2025+89.6%Miss
SRRKScholar Rock Holding Corp
Buy$44.00Sep 2025+23.0%Hit
CRBPCorbus Pharmaceuticals Holding
Buy$40.00Sep 2025−61.4%Miss
CGONCG Oncology, Inc. Common stock
Buy$75.00Sep 2025+79.3%Hit
ENGNenGene Therapeutics Inc.
Buy$25.00Sep 2025−92.8%Miss
ENGNenGene Therapeutics Inc.
Buy$25.00Sep 2025−87.6%Miss
CGONCG Oncology, Inc. Common stock
Buy$75.00Sep 2025+97.1%Hit
CGONCG Oncology, Inc. Common stock
Buy$75.00Sep 2025+95.1%Hit
MNPRMonopar Therapeutics Inc
Buy$70.00Aug 2025+198.3%Hit
KROSKeros Therapeutics Inc
Buy$20.00Aug 2025−50.9%Hit
AURAAura Biosciences Inc
Buy$22.00May 2025+7.1%Miss
ZNTLZentalis Pharmaceuticals Llc
Buy$10.00May 2025+210.5%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$40.00May 2025+53.6%Miss
FHTXFoghorn Therapeutics Inc
Buy$13.00Apr 2025+5.4%Miss
TARAProtara Therapeutics Inc
Buy$23.00Apr 2025+43.7%Miss
CRBPCorbus Pharmaceuticals Holding
Buy$50.00Mar 2025+43.1%Miss
HOWLWerewolf Therapeutics Inc
Buy$15.00Mar 2025−38.0%Miss
ENGNenGene Therapeutics Inc.
Buy$25.00Mar 2025+22.5%Miss
ENGNenGene Therapeutics Inc.
Buy$25.00Dec 2024+32.7%Miss
SRRKScholar Rock Holding Corp
Buy$50.00Nov 2024+3.4%Miss
HOWLWerewolf Therapeutics Inc
Buy$15.00Nov 2024−52.1%Miss
Prev1
Go to

Andres Y. Maldonado: analyst track record FAQ

Is Andres Y. Maldonado a good stock analyst?

Yes, by track record. Andres Y. Maldonado ranks number 288 of 589 of the analysts Quantellect scores, with an Analyst Score of 36 out of 100. Past results do not guarantee future ones.

What is Andres Y. Maldonado's win rate?

Andres Y. Maldonado's win rate is 39%. Across 41 scored calls, their rated stocks beat their sector 39% of the time over the next 12 months. On a typical call they returned −4.6% more than the sector.

What stocks and sectors does Andres Y. Maldonado cover?

Andres Y. Maldonado covers 14 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Andres Y. Maldonado's price targets accurate?

Andres Y. Maldonado's price targets are reached within 12 months 27% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Andres Y. Maldonado's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Andres Y. Maldonado rank among Wall Street analysts?

Andres Y. Maldonado ranks number 288 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.